Back to Search
Start Over
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities
- Source :
- EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
- Publication Year :
- 2015
- Publisher :
- LIPPINCOTT WILLIAMS & WILKINS, 2015.
-
Abstract
- Objectives The aim of this study was to evaluate the efficacy and safety of entecavir monotherapy in nucleos(t) ide-naive chronic hepatitis B patients and to analyse the influence of the comorbidity burden on therapy outcome. Methods We retrospectively analysed data from 237 nucleos(t) ide-naive chronic hepatitis B white patients treated with entecavir (0.5 mg/day) at 23 Spanish centres. For the efficacy and safety analyses, patients were grouped according to their baseline comorbidities. Results The mean age of the cohort was 43 years (range: 19-82 years); 73% were male, 83% were white, and 33% were hepatitis B e antigen (HBeAg) positive. At baseline, the median hepatitis B virus DNA level was 6.20 log10 IU/ml. Of the patients, 18% had cirrhosis, 9.7% had diabetes, 16.3% had hypertension, and 15.7% had obesity; 13.4% of patients had more than one comorbid condition. Virological and biochemical responses at month 36 were obtained independently of the patients' baseline comorbid condition. Of 10 HBeAg-positive patients who discontinued treatment after HBeAg seroconversion, those who had not also cleared HBsAg (six) experienced virological recurrence in a median 5.6 months. There were no treatment discontinuations due to adverse events. Three patients were diagnosed with hepatocellular carcinoma at months 12, 30 and 54, and six experienced hepatic decompensation during follow-up. The median serum creatinine levels did not increase after 36 months of treatment, even in patients with comorbidities. Conclusion Entecavir is safe, well tolerated, and highly effective, even in patients with comorbid condition(s). Discontinuation of treatment in patients who have not been cleared of HBsAg may lead to virological recurrence. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
- Subjects :
- Adult
Liver Cirrhosis
Male
Hepatitis B virus
medicine.medical_specialty
Guanine
drug safety
Antiviral Agents
White People
Young Adult
Hepatitis B, Chronic
Chronic hepatitis
Recurrence
Internal medicine
Diabetes Mellitus
medicine
Humans
chronic hepatitis B
Hepatitis B e Antigens
Obesity
Hepatitis B Antibodies
Aged
Retrospective Studies
Aged, 80 and over
Hepatitis B Surface Antigens
Hepatology
business.industry
fungi
Gastroenterology
Alanine Transaminase
Entecavir
Middle Aged
medicine.disease
Comorbidity
clinical practice
comorbidity
Creatinine
DNA, Viral
Hypertension
Female
business
Follow-Up Studies
medicine.drug
entecavir
Subjects
Details
- ISSN :
- 0954691X
- Database :
- OpenAIRE
- Journal :
- EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
- Accession number :
- edsair.doi.dedup.....f33e5c4d3803e51f12f6734647adfc47